[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 2,203
Citations 0
In This Issue of JAMA
January 10, 2017


JAMA. 2017;317(2):103-105. doi:10.1001/jama.2016.12943

Secondary hyperparathyroidism is a major complication of chronic kidney disease, particularly among patients receiving hemodialysis. In 2 parallel, randomized, placebo-controlled clinical trials, which together enrolled 1023 patients who were receiving hemodialysis and had moderate to severe secondary hyperparathyroidism, Block and colleagues evaluated the effect of etelcalcetide—a calcimimetic agent administered intravenously after each hemodialysis session—on serum parathyroid hormone (PTH) concentration. The authors report that compared with placebo, use of etelcalcetide resulted in greater reduction in serum PTH levels over 26 weeks. In an Editorial, Middleton and Wolf discuss the potential for calcimimetic therapy to improve outcomes in patients with end-stage renal disease.

First Page Preview View Large
First page PDF preview
First page PDF preview